Your session is about to expire
← Back to Search
Eribulin + Pembrolizumab for Sarcoma
Study Summary
This trial is testing a new combination of drugs to treat liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma that has Spread and did not respond to standard treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My hemoglobin level is at least 8 g/dL, transfusions included.Your bilirubin levels must not exceed a certain limit, unless you have a condition called Gilbert Syndrome.Your white blood cell count is not too low (at least 1,500/mcL).Your white blood cell count is at least 3,000/mcL.I have recovered from major side effects of previous treatments.I haven't had chemotherapy or radiotherapy in the last 3 weeks.I can provide previous tumor samples or am willing to have a biopsy.My organs and bone marrow are functioning normally.I have at least one tumor that can be measured.I am 18 years old or older.I am fully active or can carry out light work.You are pregnant or currently breastfeeding.I have brain metastases that are either untreated, causing symptoms, or need treatment for symptoms.I have not received a live vaccine in the last 30 days.You have previously had an organ transplant or a condition that weakens your immune system.I am allergic to medications similar to Eribulin or Pembrolizumab.My sarcoma type has been confirmed by a specific hospital's pathologist.I have undergone at least one chemotherapy treatment.I agree to use birth control during the study.I have not been treated with eribulin or drugs targeting immune checkpoints.You must have a certain level of platelets in your blood (at least 100,000/mcL).I have or had an autoimmune disease that could come back.I am 18 years old or older.I have had issues like severe gut infections, blockages, or cancer spread in my abdomen.I do not have any uncontrolled illnesses.I am fully active or can carry out light work.I have had pneumonitis or lung disease affecting the tissue and space around the air sacs.I have undergone at least one chemotherapy treatment before.I haven't taken high-dose steroids or other immune-weakening drugs in the last 2 weeks.
- Group 1: Leiomyosarcomas
- Group 2: Undifferentiated Pleomorphic sarcomas
- Group 3: Liposarcomas
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Pembrolizumab been utilized in any prior scientific studies?
"At this time, 995 trials are being conducted to assess the efficacy of Pembrolizumab with 132 reaching Phase 3. Of those studies, Houston is hosting a number but there exist 36946 locations wherein research related to this medication is taking place."
Is Pembrolizumab a safe medication for patients to use?
"Although no efficacy data is available, Pembrolizumab has been assigned a safety score of 2 due to some pre-existing evidence of its risk profile from Phase 2 trials."
What is the capacity of this medical trial in terms of participants?
"At the moment, this trial is not seeking participants. First posted on May 13th 2019 and last edited November 15 2022, if you're searching for other studies, there are currently 478 leiomyosarcoma trials and 995 Pembrolizumab experiments actively recruiting patients."
Are there any open slots for participation in this experimental procedure?
"This particular clinical trial has concluded its recruitment period. Initially advertised on May 13th 2019 and most recently updated November 15th 2022, participants are no longer being sought for this study. However, there are currently 478 trials related to leiomyosarcoma and 995 Pembrolizumab studies actively seeking patients."
What primary afflictions is Pembrolizumab regularly employed to ameliorate?
"Pembrolizumab has been known to effectively combat malignant neoplasms, unresectable melanoma, and cases of microsatellite instability high."
Share this study with friends
Copy Link
Messenger